INCHEON, Korea, March 09, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. presented two new study results for its immunology portfolio – SB5, a biosimilar to Humira 1 (adalimumab), and SB17, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results